Table 3 Previous studies of MMP-11 expression in human breast cancer
Type of MMP-11 analysis | Antibody used | Nb of BC cases | Population | Study design | Survival data | MMP-11 expression and localization | MMP-11 expression correlations | Year | Reference |
|---|---|---|---|---|---|---|---|---|---|
NB | NA | 92 | 92 primary BC 19 metastatic lymph nodes 91 normal tissue, 6 benign cases | Observational | no | Tumor tissue only | No association with stage, grade Positive association with ER+ | 1993 | [55] |
ISH | NA | 68 | 65 primary BC 83% Invasive (IDC/ILC), 17% in situ Size 6-40 mm 59% ER-positive | Case-control | yes | 82% of in situ BC 97% of invasive BC (IDC > ILC) | Positive association with grade and lower survival | 1994 | [9] |
NB | NA | 92 | 92 primary BC 89% invasive (IDC/ILC), 11% in situ N- and N+ | Prospective cohort | yes | NA | No association with survival | 1995 | [11] |
IHC | Monoclonal–In-house | 111 | 111 primary BC 100% invasive (IDC/ILC) 80% T1-2 39% N-, 40% N+ | Retrospective cohort | yes | 76% of invasive BC (IDC > ILC) Fibroblast-like cells in tumor stroma only | Positive association with modified SBR grade and lower survival | 1996 | [24] |
IHC ISH | Monoclonal–In-house | 100 | 100 primary BC 20 benign cases 78% invasive (IDC/ILC, with 14% metaplastic) 28% in situ 96% T1-2 N- 37%, N + 63% (26% over 4 involved nodes) | Retrospective cohort | yes | 80% of invasive BC 21% of in situ BC Fibroblast-like cells in tumor stroma only Epithelial tumor cells in metaplastic cancers | No association with grade, node statut, ER/PR Positive association with recurrence (univariate analysis only) | 1998 | [10] |
ISH | NA | 557 | 557 primary BC N- 35%, 65% N+ Tumor size 0.6-15Â cm | Retrospective cohort | yes | 89% of invasive BC Fibroblast-like cells in tumor stroma only | Positive association with younger age, higher grade, higher uPA Concomitant expression of cathepsin D, MMP-11 et uPA associated with lower survival | 2001 | [33] |
IHC | Monoclonal–In-house | 133 | 133 primary BC 100% invasive (IDC/ILC) n- 43%, N + 57% | Retrospective cohort | no | 73% of invasive BC: -tumor stroma fibroblast-like cells: 65% (IDC > ILC) -epithelial tumor cells: 26% | Stromal expression positively associated with proliferation (TopoII α and Ki67) and decreased survival | 2002 | [34] |
IHC | Monoclonal–LabVision Corporation, (Fremont, CA, USA) | 124 | 124 primary BC 100% T1-2 48% N-, 52% N+ | Case-control | yes | Fibroblast staining in 70% of invasive BC | Positive association with recurrence | 2009 | [31] |
RT-PCR IHC (subset) | Monoclonal–Santa Cruz Biotechnology (CA, USA) | 72 | 72 primary BC 75% T1-2, 25% T3-4 80% Stage I-II Paired with healthy ipsilateral breast tissue | Observational | no | Tumor tissue only | Positive association with lymph node involvement and high stage | 2010 | [29] |
IHC (tissue arrays) | Monoclonal– LabVision Corporation (Fremont, CA, USA) | 103 | 50 IDC (luminal 48%, T1-2, N + 58%) 23 ILC 14 mucinous 11 tubular / papillary 5 medullary | Observational | no | Tumour cells/fibroblast/MIC: 88/60/32% for IDC 100/91/79% for ILC 86/0/0% for mucinous 91/91/91% for tubular 100/100/100% of medullary | NA | 2010 | [32] |
ISH | NA | 30 | 30 ILC | Observational | no | 53% of invasive lobular carcinoma Epithelial cells > stromal cells Staining pattern in epithelial cells different between invasive (pancytoplasmic) and non-invasive foci (beneath the plasma membrane) | NA | 2011 | [37] |
IHC | Polyclonal- LabVision Corporation, (Fremont, CA, USA) | 192 | 192 IDC 44% N-, 56% N+ 78% Stage I-II 56% Luminal A, 12% luminal B, 17% basal-like, 15% HER2 positive | Retrospective cohort | yes | 80% of BCÂ : epithelial tumor cells 20.8% of BCÂ : tumor stroma fibroblast-like cells | Stromal expression positively associated with tumor size, high grade, tumor fibrosis, hormon-negative, HER2 positive, higher metastatic and recurrence rate No relevant association found for epithelial expression | 2013 | [12] |
IHC (tissue arrays) | Monoclonal– LabVision Corporation (Fremont, CA, USA) | 107 | 107 IDC 56% N-, 44% N+ 91% Stage I-II 43% hormone receptor positive | Observational | yes | Epithelial cancer cells: 87% (tumor center) and 97% (tumor front) Stromal cells: Fibroblasts 70% Mononucleate inflammatory cells 31%(center)-52%(invasive front) | MMP-11 expression by mononucleate inflammatory cells is associate with shorter relapse-free survival | 2015 | [50] |